Pilot study of recombinant interferon alpha-2a for treatment of infants with bronchiolitis induced by respiratory syncytial virus

J. Portnoy, Ralph Hicks, F. Pacheco, L. Olson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Eleven children with bronchiolitis induced by respiratory syncytial virus received 10,000 to 70,000 U of recombinant interferon alpha-2a per kg of body weight per day. None developed signs of toxicity, and all but one developed an antiviral state following treatment. Interferon alpha-2a appears to be safe for infants with bronchiolitis. Its efficacy for the treatment of this condition remains to be determined.

Original languageEnglish (US)
Pages (from-to)589-591
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume32
Issue number4
StatePublished - 1988
Externally publishedYes

Fingerprint

Bronchiolitis
Respiratory Syncytial Viruses
Antiviral Agents
Body Weight
Therapeutics
interferon alfa-2a

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Pilot study of recombinant interferon alpha-2a for treatment of infants with bronchiolitis induced by respiratory syncytial virus. / Portnoy, J.; Hicks, Ralph; Pacheco, F.; Olson, L.

In: Antimicrobial Agents and Chemotherapy, Vol. 32, No. 4, 1988, p. 589-591.

Research output: Contribution to journalArticle

@article{66fe27531a4e449582cde5f917063fa4,
title = "Pilot study of recombinant interferon alpha-2a for treatment of infants with bronchiolitis induced by respiratory syncytial virus",
abstract = "Eleven children with bronchiolitis induced by respiratory syncytial virus received 10,000 to 70,000 U of recombinant interferon alpha-2a per kg of body weight per day. None developed signs of toxicity, and all but one developed an antiviral state following treatment. Interferon alpha-2a appears to be safe for infants with bronchiolitis. Its efficacy for the treatment of this condition remains to be determined.",
author = "J. Portnoy and Ralph Hicks and F. Pacheco and L. Olson",
year = "1988",
language = "English (US)",
volume = "32",
pages = "589--591",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Pilot study of recombinant interferon alpha-2a for treatment of infants with bronchiolitis induced by respiratory syncytial virus

AU - Portnoy, J.

AU - Hicks, Ralph

AU - Pacheco, F.

AU - Olson, L.

PY - 1988

Y1 - 1988

N2 - Eleven children with bronchiolitis induced by respiratory syncytial virus received 10,000 to 70,000 U of recombinant interferon alpha-2a per kg of body weight per day. None developed signs of toxicity, and all but one developed an antiviral state following treatment. Interferon alpha-2a appears to be safe for infants with bronchiolitis. Its efficacy for the treatment of this condition remains to be determined.

AB - Eleven children with bronchiolitis induced by respiratory syncytial virus received 10,000 to 70,000 U of recombinant interferon alpha-2a per kg of body weight per day. None developed signs of toxicity, and all but one developed an antiviral state following treatment. Interferon alpha-2a appears to be safe for infants with bronchiolitis. Its efficacy for the treatment of this condition remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=0023839993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023839993&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 589

EP - 591

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -